Skip to main content

Table 1 Baseline characteristics for the study population

From: Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matched analysis

Parameter All (n = 82) No ASS (n = 64) ASS (n = 18) p
Agea 71.1 [62.1–75.1] 71.6 [62.1–76] 70.6 [64–72.1] 0.779
Sex     1.0
 Female 29 (35.4%) 23 (35.9%) 6 (33.3%)  
 Male 53 (64.6%) 41 (64.1%) 12 (66.7%)  
ASA score     0.09
 ASA II 16 (19.5%) 11 (17.2%) 5 (27.8%)  
 ASA III 65 (79.3%) 53 (82.8%) 12 (66.7%)  
 ASA IV 1 (1.2%) 0 (0%) 1 (5.6%)  
BMI 24.2 [22.1–26] 24.3 [22.5–26.1] 23.2 [21.9–26] 0.398
Serum CA 19–9 (U/ml)a 88.4 [27–368] 96.7 [27.3–381.] 49.5 [13.5–339] 0.292
Platelet counta (G/l) 232 [178–279] 235 [177–310] 225 [181–272] 0.760
Type of surgery     0.474
 PD 55 (67.1%) 45 (70.3%) 10 (55.6%)  
 DP 18 (22%) 13 (20.3%) 5 (27.8%)  
 TP 9 (11%) 6 (9.4%) 3 (16.7%)  
RBC during surg. (units)a     0.404
 Yes 9 (11%) 6 (9.4%) 3 (16.7%)  
 No 73 (89%) 58 (90.6%) 15 (83.3%)
Additional venous resection     0.778
 Yes 25 (30.5%) 19 (29.7%) 6 (33.3%)  
 No 57 (69.5%) 45 (70.3%) 12 (66.7%)  
Tumor diameter max (cm)a 3.3 [2.5–4.3] 3.2 [2.5–4.4] 3.3 [2.3–4.2] 0.771
T stage     
 T1 + 2 6 (7.3%) 4 (6.2%) 2 (11.1%) 0.608
 T3 76 (92.7%) 60 (93.8%) 16(88.9%)  
N stage     1.0
 N0 25 (30.5%) 20 (31.2%) 5 (27.8%)  
 N1 57 (69.5%) 44 (68.8%) 13 (72.2%)  
ELNa 26 [19–35] 25 [19–34] 33 [27–39] *0.007
LNRa 0.07 [0.0–0.16] 0.09 [0.0–0.17] 0.04 [0.0–0.08] 0.754
Grading     
 G1 1 (1.2%) 1 (1.6%) 0 (0%)  
 G2 23 (28%) 17 (26.6%) 6 (33.3%)  
 G3 58 (70.7%) 46 (71.9%) 12 (66.7%)  
Perineural invasion     0.246
 Pn0 11 (13.4%) 7 (10.9%) 4 (22.2%)  
 Pn1 71 (86.6%) 57 (89.1%) 14 (77.8%)  
Vascular invasion     1.0
 V0 68 (82.9%) 53 (82.8%) 15 (83.3%)  
 V1 14 (17.1%) 11 (17.2%) 3 (16.7%)  
Lymphovascular invasion     0.282
 L0 49 (59.8%) 36 (56.2%) 13 (72.2%)  
 L1 33 (40.2%) 28 (43.8%) 5 (27.8%)  
R status     0.457
 R0 wide 29 (35.4%) 24 (37.5%) 5 (27.8%)  
 R0 narrow 35 (42.7%) 25 (39.1%) 10 (55.6%)  
 R1 18 (22%) 15 (23.4%) 3 (16.7%)  
Adjuvant therapy     0.282
 Yes 48 (58.5%) 36 (56.2%) 12 (66.7%)  
 No 8 (9.8%) 8 (12.5%) 0 (0%)  
 Unknown 26 (31.7%) 20 (31.2%) 6 (33.3%)  
  1. Differences in baseline characteristics were assessed by Fisher’s exact test for categorical and Mann–Whitney-U test for continuous variables
  2. ASA American Society of Anesthesiologists Score, BMI body mass index, PD pancreaticoduodenectomy, DP distal pancreatectomy, total pancreatectomy, RBC packed red blood cells, ELN examined lymph nodes, LNR lymph node ratio
  3. aValues expressed as median [interquartile range]
  4. *p < 0.05